Management of Myositis-Related Interstitial Lung Disease

Chest. 2016 Nov;150(5):1118-1128. doi: 10.1016/j.chest.2016.04.007. Epub 2016 Apr 19.

Abstract

Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature.

Keywords: interstitial lung disease; myositis; treatment.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Biomarkers / analysis
  • Diagnostic Imaging
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / etiology*
  • Lung Diseases, Interstitial / therapy*
  • Myositis / complications*
  • Myositis / diagnosis

Substances

  • Biomarkers
  • Immunosuppressive Agents